Sotera Health Announces Q4 and Full-Year 2025 Financial Results Release
- Financial Results Announcement: Sotera Health plans to release its financial results for Q4 and full-year 2025 before the market opens on February 24, 2026, highlighting its critical business performance in the healthcare sector.
- Management Conference Call: Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the company's operational highlights and financial results, enhancing investor confidence in the company's future prospects.
- Live Webcast Availability: The conference call will be accessible via a live webcast on the company's Investor Relations section, allowing investors to receive real-time updates, with a replay available later that day to ensure widespread information dissemination.
- Company Background: Sotera Health is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services for the healthcare industry, committed to its mission of Safeguarding Global Health through its three business units: Sterigenics, Nordion, and Nelson Labs.
Trade with 70% Backtested Accuracy
Analyst Views on SHC
About SHC
About the author
Sotera Health Announces Q4 and Full-Year 2025 Financial Results Release
- Financial Results Announcement: Sotera Health plans to release its financial results for Q4 and full-year 2025 before the market opens on February 24, 2026, highlighting its critical business performance in the healthcare sector.
- Management Conference Call: Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the company's operational highlights and financial results, enhancing investor confidence in the company's future prospects.
- Live Webcast Availability: The conference call will be accessible via a live webcast on the company's Investor Relations section, allowing investors to receive real-time updates, with a replay available later that day to ensure widespread information dissemination.
- Company Background: Sotera Health is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services for the healthcare industry, committed to its mission of Safeguarding Global Health through its three business units: Sterigenics, Nordion, and Nelson Labs.
Sotera Health Appoints New Independent Director
- New Board Member: Sotera Health Company has appointed Richard G. Kyle as a new independent director, who will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee, enhancing the company's governance structure.
- Rich Leadership Experience: Kyle previously served as CEO of Timken, where he drove financial transformation and strategic diversification, showcasing his strong background in global operations and financial management.
- Diverse Background: Before becoming CEO, Kyle held various senior leadership roles at Timken, accumulating extensive industry experience that will provide crucial support for Sotera Health's future growth.
- Strategic Value: Sotera Health's CEO Michael B. Petras emphasized that Kyle's leadership experience and governance expertise will serve as valuable assets for the company's continued growth, further solidifying its market position in the healthcare industry.
Warburg Pincus Sells 9.72M Shares of Sotera Health for $158.7M
- Share Sale: Warburg Pincus executed an indirect sale of 9.72 million shares of Sotera Health for a total of $158.7 million, demonstrating its strategic timing in capitalizing on market liquidity.
- Ownership Reduction: This transaction accounted for a 22.18% reduction in Warburg Pincus's indirect stake, leaving 34.1 million shares indirectly held, indicating a continued strategy of divestment.
- Market Performance: Sotera Health's stock closed at $16.84 on the transaction day, reflecting a 31.25% year-over-year increase, which provided favorable conditions for executing a large block sale.
- Investor Insight: Despite the share reduction, Warburg Pincus retains over 34 million shares, indicating confidence in Sotera Health's growth potential, which is crucial for investors to monitor institutional ownership trends.
Noteworthy SHC Put and Call Options Set for August 2026
Put Contract Overview: The $15.00 put contract has a bid of 5 cents, allowing investors to buy shares at a lower cost basis of $14.95, which is a 13% discount from the current price of $17.20. There is a 73% chance the contract may expire worthless, offering a potential 0.33% return on cash commitment.
Call Contract Overview: The $22.50 call contract has a bid of 20 cents, and if shares are purchased at $17.20 and the call is sold, it could yield a total return of 31.98% if exercised. There is a 64% chance this contract may also expire worthless, providing a potential 1.16% additional return.
Volatility Insights: The implied volatility for the put contract is 48% and for the call contract is 52%, while the actual trailing twelve-month volatility is calculated at 42%.
YieldBoost Concept: Both the put and call contracts offer a "YieldBoost," with the put providing a 0.50% annualized return if it expires worthless, and the call offering a 1.73% annualized return under similar conditions.
Sotera Health Sells at Significant Discount Despite Top-Notch Margins, According to Analyst
Investor Interest in Sotera Health: Sotera Health is gaining attention from investors due to reduced litigation risks and improved free cash flow, highlighting its integrated sterilization platform and strong customer base.
William Blair Coverage Initiation: William Blair has initiated coverage on Sotera Health, noting its leadership in sterilization solutions and the competitive advantages of its integrated service offerings and high margins.
Valuation Discount Compared to Peers: Despite a strong financial outlook, Sotera is trading at a significant discount to its peers, with potential for upside as free cash flow improves and interest expenses decrease.
Re-Rating Potential: As legal risks diminish, analysts expect Sotera's stock to re-rate towards its long-term average EBITDA multiple, suggesting a potential 45% upside by 2027 based on future earnings estimates.
Valvoline Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations
Analyst Coverage Initiations: Mizuho initiated coverage on Avalo Therapeutics with an Outperform rating and a price target of $39, while Raymond James gave Lexeo Therapeutics a Strong Buy rating with a target of $25.
Valvoline and Serve Robotics Ratings: Roth Capital initiated coverage on Valvoline with a Buy rating and a price target of $42, and Oppenheimer rated Serve Robotics as Outperform with a target of $20.
Sotera Health Coverage: William Blair initiated coverage on Sotera Health with an Outperform rating, although no price target was specified.
Current Stock Prices: As of Wednesday, Avalo Therapeutics closed at $19.25, Lexeo Therapeutics at $9.11, Valvoline at $30.05, Serve Robotics at $9.55, and Sotera Health at $16.81.
Sotera Health Announces Q4 and Full-Year 2025 Financial Results Release
- Financial Results Announcement: Sotera Health plans to release its financial results for Q4 and full-year 2025 before the market opens on February 24, 2026, highlighting its critical business performance in the healthcare sector.
- Management Conference Call: Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the company's operational highlights and financial results, enhancing investor confidence in the company's future prospects.
- Live Webcast Availability: The conference call will be accessible via a live webcast on the company's Investor Relations section, allowing investors to receive real-time updates, with a replay available later that day to ensure widespread information dissemination.
- Company Background: Sotera Health is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services for the healthcare industry, committed to its mission of Safeguarding Global Health through its three business units: Sterigenics, Nordion, and Nelson Labs.
Sotera Health Appoints New Independent Director
- New Board Member: Sotera Health Company has appointed Richard G. Kyle as a new independent director, who will serve on the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee, enhancing the company's governance structure.
- Rich Leadership Experience: Kyle previously served as CEO of Timken, where he drove financial transformation and strategic diversification, showcasing his strong background in global operations and financial management.
- Diverse Background: Before becoming CEO, Kyle held various senior leadership roles at Timken, accumulating extensive industry experience that will provide crucial support for Sotera Health's future growth.
- Strategic Value: Sotera Health's CEO Michael B. Petras emphasized that Kyle's leadership experience and governance expertise will serve as valuable assets for the company's continued growth, further solidifying its market position in the healthcare industry.
Warburg Pincus Sells 9.72M Shares of Sotera Health for $158.7M
- Share Sale: Warburg Pincus executed an indirect sale of 9.72 million shares of Sotera Health for a total of $158.7 million, demonstrating its strategic timing in capitalizing on market liquidity.
- Ownership Reduction: This transaction accounted for a 22.18% reduction in Warburg Pincus's indirect stake, leaving 34.1 million shares indirectly held, indicating a continued strategy of divestment.
- Market Performance: Sotera Health's stock closed at $16.84 on the transaction day, reflecting a 31.25% year-over-year increase, which provided favorable conditions for executing a large block sale.
- Investor Insight: Despite the share reduction, Warburg Pincus retains over 34 million shares, indicating confidence in Sotera Health's growth potential, which is crucial for investors to monitor institutional ownership trends.
Noteworthy SHC Put and Call Options Set for August 2026
Put Contract Overview: The $15.00 put contract has a bid of 5 cents, allowing investors to buy shares at a lower cost basis of $14.95, which is a 13% discount from the current price of $17.20. There is a 73% chance the contract may expire worthless, offering a potential 0.33% return on cash commitment.
Call Contract Overview: The $22.50 call contract has a bid of 20 cents, and if shares are purchased at $17.20 and the call is sold, it could yield a total return of 31.98% if exercised. There is a 64% chance this contract may also expire worthless, providing a potential 1.16% additional return.
Volatility Insights: The implied volatility for the put contract is 48% and for the call contract is 52%, while the actual trailing twelve-month volatility is calculated at 42%.
YieldBoost Concept: Both the put and call contracts offer a "YieldBoost," with the put providing a 0.50% annualized return if it expires worthless, and the call offering a 1.73% annualized return under similar conditions.
Sotera Health Sells at Significant Discount Despite Top-Notch Margins, According to Analyst
Investor Interest in Sotera Health: Sotera Health is gaining attention from investors due to reduced litigation risks and improved free cash flow, highlighting its integrated sterilization platform and strong customer base.
William Blair Coverage Initiation: William Blair has initiated coverage on Sotera Health, noting its leadership in sterilization solutions and the competitive advantages of its integrated service offerings and high margins.
Valuation Discount Compared to Peers: Despite a strong financial outlook, Sotera is trading at a significant discount to its peers, with potential for upside as free cash flow improves and interest expenses decrease.
Re-Rating Potential: As legal risks diminish, analysts expect Sotera's stock to re-rate towards its long-term average EBITDA multiple, suggesting a potential 45% upside by 2027 based on future earnings estimates.
Valvoline Analyst Starts Coverage Optimistically; Check Out Thursday's Top 5 Initiations
Analyst Coverage Initiations: Mizuho initiated coverage on Avalo Therapeutics with an Outperform rating and a price target of $39, while Raymond James gave Lexeo Therapeutics a Strong Buy rating with a target of $25.
Valvoline and Serve Robotics Ratings: Roth Capital initiated coverage on Valvoline with a Buy rating and a price target of $42, and Oppenheimer rated Serve Robotics as Outperform with a target of $20.
Sotera Health Coverage: William Blair initiated coverage on Sotera Health with an Outperform rating, although no price target was specified.
Current Stock Prices: As of Wednesday, Avalo Therapeutics closed at $19.25, Lexeo Therapeutics at $9.11, Valvoline at $30.05, Serve Robotics at $9.55, and Sotera Health at $16.81.
